Selected Publications
Ghilardi, G., Fraietta, J. A., Gerson, J. N., Van Deerlin, V. M., Morrissette, J. J. D., Caponetti, G. C., Paruzzo, L., Harris, J. C., Chong, E. A., Susanibar Adaniya, S. P., Svoboda, J., Nasta, S. D., Ugwuanyi, O. H., Landsburg, D. J., Fardella, E., Waxman, A. J., Chong, E. R., Patel, V., Pajarillo, R., Kulikovskaya, I., Lieberman, D. B., Cohen, A. D., Levine, B. L., Stadtmauer, E. A., Frey, N. V., Vogl, D. T., Hexner, E. O., Barta, S. K., Porter, D. L., Garfall, A. L., Schuster, S. J., June, C. H., Ruella, M.: T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy Nat Med 30 (4): 984-989,2024.
Bagley, S. J., Logun, M., Fraietta, J. A., Wang, X., Desai, A. S., Bagley, L. J., Nabavizadeh, A., Jarocha, D., Martins, R., Maloney, E., Lledo, L., Stein, C., Marshall, A., Leskowitz, R., Jadlowsky, J. K., Christensen, S., Oner, B. S., Plesa, G., Brennan, A., Gonzalez, V., Chen, F., Sun, Y., Gladney, W., Barrett, D., Nasrallah, M. P., Hwang, W. T., Ming, G. L., Song, H., Siegel, D. L., June, C. H., Hexner, E. O., Binder, Z. A., O'Rourke, D. M.: Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results Nat Med 30 (5): 1320-1329,2024.
Wang, Y., He, S., Calendo, G., Bui, T., Tian, Y., Lee, C. Y., Zhou, Y., Zhao, X., Abraham, C., Mo, W., Chen, M., Sanders-Braggs, R., Madzo, J., Issa, J. P., Hexner, E. O., Wiest, D. L., Reshef, R., Xue, H. H., Zhang, Y.: Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1-mediated immune suppression during GVHD Blood 143 (2): 166-177,2024.
Sung, A. D., Koll, T., Gier, S. H., Racioppi, A., White, G., Lew, M., Free, M., Agarwal, P., Bohannon, L. M., Johnson, E. J., Selvan, B., Babushok, D. V., Frey, N. V., Gill, S. I., Hexner, E. O., Martin, M., Perl, A. E., Pratz, K. W., Luger, S. M., Chao, N. J., Fisher, A. L., Stadtmauer, E. A., Porter, D. L., Loren, A. W., Bhatt, V. R., Gimotty, P. A., McCurdy, S. R.: Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients Transplant Cell Ther 30 (4): 415 e1-415 e16,2024.
Spyrou, N., Akahoshi, Y., Kowalyk, S., Morales, G., Beheshti, R., Aguayo-Hiraldo, P., Al Malki, M. M., Ayuk, F., Bader, P., Baez, J., Capellini, A., Choe, H., DeFilipp, Z., Eder, M., Eng, G., Etra, A., Gleich, S., Grupp, S. A., Hexner, E., Hoepting, M., Hogan, W. J., Kasikis, S., Katsivelos, N., Khan, A., Kitko, C. L., Kraus, S., Kwon, D., Merli, P., Portelli, J., Qayed, M., Reshef, R., Schechter, T., Vasova, I., Wolfl, M., Wudhikarn, K., Young, R., Holler, E., Chen, Y. B., Nakamura, R., Levine, J. E., Ferrara, J. L. M.: A Day 14 Endpoint for Acute GVHD Clinical Trials Transplant Cell Ther 30 (4): 421-432,2024.
Rios, C. A. O., Qayed, M., Etra, A. M., Reshef, R., Newcomb, R., Yuhasz, N., Hexner, E. O., Aguayo-Hiraldo, P., Merli, P., Hogan, W. J., Weber, D., Kitko, C. L., Ayuk, F., Eder, M., Grupp, S. A., Kraus, S., Sandhu, K., Ullrich, E., Vasova, I., Wolfl, M., Baez, J., Beheshti, R., Eng, G., Gleich, S., Katsivelos, N., Kowalyk, S., Louloudis, I. E., Morales, G., Spyrou, N., Young, R., Nakamura, R., Levine, J. E., Ferrara, J. L. M., Akahoshi, Y.: Differences in acute graft-versus-host disease (GVHD) severity and its outcomes between Black and White patients Transplant Cell Ther : 2024.
Tefferi, A., Barosi, G., Passamonti, F., Hernandez-Boluda, J. C., Bose, P., Dohner, K., Ellis, M., Gangat, N., Garcia, J. S., Gisslinger, H., Gotlib, J., Guglielmelli, P., Gupta, V., Harrison, C. N., Hexner, E. O., Hobbs, G. S., Kiladjian, J. J., Koschmieder, S., Kroger, N., Kuykendall, A. T., Loscocco, G. G., Mascarenhas, J. O., Masarova, L., Mesa, R., Mora, B., Odenike, O., Oh, S. T., Pardanani, A. D., Patel, A. A., Pemmaraju, N., Rambaldi, A., Rampal, R. K., Sirhan, S., Szuber, N., Talpaz, M., Vachhani, P., Vannucchi, A. M., Barbui, T.: Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis Blood : 2024.
Qayed, M., Kapoor, U., Gillespie, S., Westbrook, A., Aguayo-Hiraldo, P., Ayuk, F. A., Aziz, M., Baez, J., Choe, H., DeFilipp, Z., Etra, A., Grupp, S. A., Hexner, E., Holler, E., Hogan, W. J., Kowalyk, S., Merli, P., Morales, G., Nakamura, R., Pulsipher, M. A., Schechter, T., Shah, J., Spyrou, N., Srinagesh, H. K., Wolfl, M., Yanik, G., Young, R., Kitko, C. L., Ferrara, J. L. M., Levine, J. E.: A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD Transplant Cell Ther 30 (6): 603 e1-603 e11,2024.
Hexner, E. O.: The splendor and the tyranny of JAK inhibition Haematologica 109 (2): 369-370,2024.
Gotlib, J., Gerds, A. T., Abdelmessieh, P., Ali, H., Castells, M., Dunbar, A., Fein Revell, R., George, T. I., Green, S., Gundabolu, K., Hexner, E., Jain, T., Jamieson, C., Kaesberg, P. R., Kuykendall, A. T., Madanat, Y., Manchanda, N., Masarova, L., May, J., McMahon, B., Mohan, S. R., Nadiminti, K. V., Oh, S., Palmer, J., Patel, A., Patel, A. A., Podoltsev, N., Rein, L., Salit, R., Talpaz, M., Wadleigh, M., Wall, S., Bergman, M. A., Hochstetler, C.: NCCN Guidelines(R) Insights: Systemic Mastocytosis, Version 3.2024 J Natl Compr Canc Netw 22 (2D): 2024.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-151
3400 Civic Center Boulevard
Philadelphia,
PA
19104
Phone: 215-614-1847
Patient appointments: 800-789-7366